Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

BioAge Labs, Inc.

NASDAQ: BIOA · Life Sciences · 3 alerts · CIK 1709941

Share price
$5.22Close, Nov 16
Market cap
$240M
Shares outstanding
45.96MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioAge Labs, Inc. filings on SEC EDGAR ↗

4:15 PM ET 8-K
Clinical Trial Data

BioAge Labs Clinical Trial Data

BioAge Labs announced the first participant has been dosed in its QUELL-DME Phase 2 clinical trial evaluating BGE-102, an oral NLRP3 inhibitor, for the treatment of diabetic macular edema. The 180-participant trial will evaluate the drug as both a monotherapy and in combination with anti-VEGF therapy, with topline results expected in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.